Zoetis Stock Price, News & Analysis (NYSE:ZTS)

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Zoetis declared a quarterly dividend on Thursday, October 3rd. Shareholders of record on Tuesday, October 22nd will be paid a dividend of $0.164 per share on Monday, December 2nd. This represents a $0.66 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date is Monday, October 21st. View Zoetis' Dividend History.

Zoetis declared that its Board of Directors has approved a share repurchase plan on Wednesday, December 12th 2018, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 4.7% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's management believes its shares are undervalued.

Zoetis Inc (NYSE:ZTS) posted its quarterly earnings data on Tuesday, August, 6th. The company reported $0.90 EPS for the quarter, beating analysts' consensus estimates of $0.82 by $0.08. The firm earned $1.55 billion during the quarter, compared to analysts' expectations of $1.51 billion. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The business's quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.77 EPS. View Zoetis' Earnings History.

Zoetis is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Zoetis.

Zoetis will be holding an earnings conference call on Thursday, November 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Zoetis issued an update on its FY19 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of $3.53-3.60 for the period, compared to the Thomson Reuters consensus estimate of $3.49. The company issued revenue guidance of $6.18-6.28 billion, compared to the consensus revenue estimate of $6.19 billion.

15 Wall Street analysts have issued 1-year price objectives for Zoetis' stock. Their forecasts range from $86.00 to $145.00. On average, they anticipate Zoetis' stock price to reach $124.40 in the next year. This suggests that the stock has a possible downside of 1.7%. View Analyst Price Targets for Zoetis.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.

News articles about ZTS stock have trended negative this week, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zoetis earned a daily sentiment score of -2.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Zoetis.

Zoetis saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 4,420,000 shares, an increase of 30.8% from the August 30th total of 3,380,000 shares. Based on an average daily trading volume, of 1,890,000 shares, the short-interest ratio is presently 2.3 days. Approximately 0.9% of the company's stock are short sold. View Zoetis' Current Options Chain.

Some companies that are related to Zoetis include Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Bayer (BAYRY) and Allergan (AGN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Transocean (RIG), Gran Tierra Energy (GTE) and Och-Ziff Capital Management Group (OZM).

Zoetis' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Artemis Investment Management LLP (0.17%), Hexavest Inc. (0.08%), Gofen & Glossberg LLC IL (0.06%), Polaris Greystone Financial Group LLC (0.04%), Copper Rock Capital Partners LLC (0.04%) and Neville Rodie & Shaw Inc. (0.03%). Company insiders that own Zoetis stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.

ZTS stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Decatur Capital Management Inc., IMS Capital Management, Gofen & Glossberg LLC IL, Crossmark Global Holdings Inc., Neville Rodie & Shaw Inc., Everence Capital Management Inc. and Private Trust Co. NA. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.

ZTS stock was acquired by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, State of Alaska Department of Revenue, Park National Corp OH, Pacer Advisors Inc., Hexavest Inc., Cypress Capital Group, Bath Savings Trust Co and Fulton Bank N.A.. View Insider Buying and Selling for Zoetis.

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZTS stock can currently be purchased for approximately $126.59.

Zoetis has a market capitalization of $60.45 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.View Additional Information About Zoetis.

The official website for Zoetis is http://www.zoetis.com/.

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]